209 related articles for article (PubMed ID: 1898848)
1. Early combination of selegiline and low-dose levodopa as initial symptomatic therapy in Parkinson's disease. Experience in 26 patients receiving combined therapy for 26 months.
Elizan TS; Moros DA; Yahr MD
Arch Neurol; 1991 Jan; 48(1):31-4. PubMed ID: 1898848
[TBL] [Abstract][Full Text] [Related]
2. Selegiline use to prevent progression of Parkinson's disease. Experience in 22 de novo patients.
Elizan TS; Yahr MD; Moros DA; Mendoza MR; Pang S; Bodian CA
Arch Neurol; 1989 Dec; 46(12):1275-9. PubMed ID: 2511824
[TBL] [Abstract][Full Text] [Related]
3. Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients.
Elizan TS; Yahr MD; Moros DA; Mendoza MR; Pang S; Bodian CA
Arch Neurol; 1989 Dec; 46(12):1280-3. PubMed ID: 2511825
[TBL] [Abstract][Full Text] [Related]
4. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
Lees AJ
BMJ; 1995 Dec; 311(7020):1602-7. PubMed ID: 8555803
[TBL] [Abstract][Full Text] [Related]
5. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.
BMJ; 1993 Aug; 307(6902):469-72. PubMed ID: 8400928
[TBL] [Abstract][Full Text] [Related]
6. L-deprenyl (selegiline) added to Sinemet CR in the management of Parkinson's disease patients with motor response fluctuations.
Cedarbaum JM; Toy LH; Green-Parsons A
Clin Neuropharmacol; 1991 Jun; 14(3):228-34. PubMed ID: 1906374
[TBL] [Abstract][Full Text] [Related]
7. Experience with selegiline and levodopa in advanced Parkinson's disease.
Lieberman A; Fazzini E
Acta Neurol Scand Suppl; 1991; 136():66-9. PubMed ID: 1801539
[TBL] [Abstract][Full Text] [Related]
8. Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease.
Presthus J; Hajba A
Acta Neurol Scand Suppl; 1983; 95():127-33. PubMed ID: 6428145
[TBL] [Abstract][Full Text] [Related]
9. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
Heinonen EH; Myllylä V
Drug Saf; 1998 Jul; 19(1):11-22. PubMed ID: 9673855
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease.
Lew MF; Pahwa R; Leehey M; Bertoni J; Kricorian G;
Curr Med Res Opin; 2007 Apr; 23(4):741-50. PubMed ID: 17407630
[TBL] [Abstract][Full Text] [Related]
11. Role of selegiline as initial monotherapy in early Parkinson's disease.
Bhatia M; Jain S; Maheshwari MC
J Assoc Physicians India; 1994 Jan; 42(1):30-2. PubMed ID: 7836244
[TBL] [Abstract][Full Text] [Related]
12. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
13. Some new aspects of the effect of (-)deprenyl in Parkinson's disease--a retrospective study.
Málly J
J Neural Transm Park Dis Dement Sect; 1992; 4(2):155-64. PubMed ID: 1571079
[TBL] [Abstract][Full Text] [Related]
14. Selegiline in the treatment of Parkinson's disease--long term experience.
Yahr MD; Elizan TS; Moros D
Acta Neurol Scand Suppl; 1989; 126():157-61. PubMed ID: 2515721
[TBL] [Abstract][Full Text] [Related]
15. Selegiline and levodopa in early or moderately advanced Parkinson's disease: a double-blind controlled short- and long-term study.
Sivertsen B; Dupont E; Mikkelsen B; Mogensen P; Rasmussen C; Boesen F; Heinonen E
Acta Neurol Scand Suppl; 1989; 126():147-52. PubMed ID: 2515720
[TBL] [Abstract][Full Text] [Related]
16. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
Larsen JP; Boas J
Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
Brannan T; Yahr MD
Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
[TBL] [Abstract][Full Text] [Related]
18. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
[TBL] [Abstract][Full Text] [Related]
19. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
[TBL] [Abstract][Full Text] [Related]
20. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
Olanow CW; Hauser RA; Gauger L; Malapira T; Koller W; Hubble J; Bushenbark K; Lilienfeld D; Esterlitz J
Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
